Colchicine drug-to-drug interactions

  • US 10,383,820 B2
  • Filed: 10/09/2018
  • Issued: 08/20/2019
  • Est. Priority Date: 12/20/2017
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating a colchicine sensitive disorder, comprising orally administering a liquid colchicine solution to a human subject having a colchicine sensitive disorder in an effective amount to treat the disorder, wherein the colchicine sensitive disorder is selected from gout, familial Mediterranean fever (FMF), pericarditis, Behç

  • et'"'"'s disease, atrial fibrillation, amyloidosis, calcium pyrophosphate deposition disease (pseudogout), cirrhosis of the liver, or sarcoid arthritis,wherein the liquid colchicine solution comprises a concentration of colchicine of 0.01-1.0 mg/ml, 0.1-0.3% w/v of anhydrous citric acid, 0.8-1.6% w/v of dibasic sodium phosphate heptahydrate, 0.1-0.2% w/v of a thickening agent, a preservative, glycols, and water, and wherein the liquid colchicine solution is stable for at least one month at refrigerated and ambient temperature conditions.

View all claims

    Thank you for your feedback